1. Home
  2. EBF vs NMRA Comparison

EBF vs NMRA Comparison

Compare EBF & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ennis Inc.

EBF

Ennis Inc.

HOLD

Current Price

$17.68

Market Cap

436.2M

ML Signal

HOLD

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

424.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBF
NMRA
Founded
1909
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
436.2M
424.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
EBF
NMRA
Price
$17.68
$2.08
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$8.00
AVG Volume (30 Days)
203.4K
1.1M
Earning Date
12-19-2025
11-06-2025
Dividend Yield
5.67%
N/A
EPS Growth
3.59
N/A
EPS
1.63
N/A
Revenue
$388,344,000.00
N/A
Revenue This Year
$0.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.30
$0.61
52 Week High
$22.01
$11.57

Technical Indicators

Market Signals
Indicator
EBF
NMRA
Relative Strength Index (RSI) 57.53 40.16
Support Level $16.51 $2.13
Resistance Level $17.91 $2.36
Average True Range (ATR) 0.32 0.18
MACD 0.08 -0.05
Stochastic Oscillator 80.82 4.62

Price Performance

Historical Comparison
EBF
NMRA

About EBF Ennis Inc.

Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: